Tag Archives: ADDRESS II Phase IIb multicenter study

Merck: Results of the ADDRESS II Phase IIb multicenter study on atacicept in patients with systemic lupus erythematosus

Posted on 15, November 2016 by

Data presented at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting (Abstract Number: 12L) DARMSTADT, 15-Nov-2016 — /EuropaWire/ — Merck, a leading science and technology company, today announced the results of the ADDRESS II Phase IIb, … Read the full press release →

Posted in Germany, Healthcare, Pharma & Biotech, Science

Tagged , , ,